Dr. Vivek Roy, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 47
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 902
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME82048
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Jacksonville, FL
Medical groups
- Mayo Clinic Jacksonville (1,615 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 902
- Services billed
- 129,942
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 13,200 | 20 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11,220 | 20 |
| Injection, pembrolizumab, 1 mg | 11,202 | 47 |
| Injection, fosaprepitant, 1 mg | 7,200 | 45 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 6,560 | 18 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 6,480 | 30 |
| Injection, oxaliplatin, 0.5 mg | 5,100 | 15 |
| Injection, nivolumab, 1 mg | 4,720 | 12 |
| Injection, paclitaxel, 1 mg | 3,672 | 21 |
| Injection, denosumab, 1 mg | 3,360 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Jacksonville, FL | 62 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Jacksonville, FL | 20 |
| Jakafi (ruxolitinib phosphate) | 16 |
| Oxycodone Hcl Other prescribers in Jacksonville, FL | 14 |
| Dexamethasone Other prescribers in Jacksonville, FL | 13 |
| Tacrolimus Other prescribers in Jacksonville, FL | 13 |
| Pantoprazole Sodium Other prescribers in Jacksonville, FL | 11 |
| Brukinsa (zanubrutinib) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $169 in total to this clinician.
| Medexus Pharma, Inc. | $169 |
|---|
| Food and Beverage | $169 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 2 companies. The companies reported $168,914 in research payments for these studies, mostly to the institutions running them.
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. · Active, not recruiting · NCT06158841 - A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Celgene Corporation - A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma …
Celgene Corporation - M23-001 - Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. - Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. - Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. · Active, not recruiting · NCT06223516 - Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.